Description of Collaborative Activity: |
NIH has been working with the FDA to create the NIH-FDA Joint Leadership Council, through which senior leaders from both agencies will address ways to facilitate new processes, such as FDA review of combination therapies and its consideration of rare disease trials with fewer patients enrolled. Medicines that have been developed and approved for one indication are sometimes useful for the treatment of other diseases, leading to enormous savings in development time and costs. |
